Saracatinib impairs maintenance of human T-ALL by targeting the LCK tyrosine kinase in cells displaying high level of lipid rafts

Leukemia. 2018 Sep;32(9):2062-2065. doi: 10.1038/s41375-018-0081-5. Epub 2018 Feb 28.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • Benzodioxoles / pharmacology*
  • Cell Line, Tumor
  • Disease Models, Animal
  • Humans
  • Lymphocyte Specific Protein Tyrosine Kinase p56(lck) / antagonists & inhibitors*
  • Membrane Microdomains / drug effects*
  • Membrane Potential, Mitochondrial
  • Mice
  • Neoplastic Stem Cells / drug effects
  • Neoplastic Stem Cells / metabolism
  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / metabolism*
  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • Quinazolines / pharmacology*
  • Reactive Oxygen Species / metabolism
  • Xenograft Model Antitumor Assays

Substances

  • Antineoplastic Agents
  • Benzodioxoles
  • Quinazolines
  • Reactive Oxygen Species
  • saracatinib
  • Lymphocyte Specific Protein Tyrosine Kinase p56(lck)